Published in Medical Letter on the CDC and FDA, November 12th, 2006
The abstract was entitled: Phase I study of the safety and pharmacokinetics of staphylococcal protein A in healthy adults. PRTX-100 is in development for autoimmune disorders including rheumatoid arthritis and idiopathic thrombocytopenic purpura (ITP).
As previously announced, the data demonstrated that in a single dose Phase I clinical trial, PRTX 100 was safe and well tolerated. There were no serious adverse events deaths and no major safety lab or vital sign...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.